Location: Home >> News >> All News >> Health >> Content

Glaxo, Xenoport's drug gets FDA nod for new use

2012-6-08 09:56 

(Reuters) - Drugmaker XenoPort Inc and partner GlaxoSmithKline Plc said the U.S. Food and Drug Administration had approved their drug to treat shingles-related nerve pain. However, XenoPort's shares fell as much as 13 percent on concerns that a contractual dispute between Xenoport and GSK over the drug, Horizant, could now take longer to resolve, RBC Capital analyst Michael Yee said. The two partners are in a legal battle after XenoPort alleged that GSK had breached a contractual obligation.

Thu Jun 7, 2012 1:32pm EDT



Click here to read the whole story

Return to GoPath by clicking back arrow on the webpage

Print    Close
Prev Next


seccode Change another
View all reply【0 users already expressed their views】
Commend news
Latest news